Phibro Animal Health Corporation

NASDAQ:PAHC

Drug Manufacturers - Specialty & Generic

Healthcare
$35.57 +1.23%

+$0.38 today

Market cap
$1.44B
Beta
0.46
P/E (TTM)
13.3
EPS (TTM)
$2.35
Dividend yield
1.54%
52W Low $23.57High $60.08

Volume 0.11M

Average 0.37M

PAHC Inventory

Cash effect of the change in inventory; building inventory consumes cash.

Phibro Animal Health CorporationNASDAQ: PAHC

Inventory · Q3 FY2026 · quarter ended Mar 2026

Inventory grows, but more slowly than its trailing trend

Q3 FY2026 inventory of $19.33M (cash outflow) rose 40.8% year over year, behind the +233.4% change in trailing-twelve-month inventory. Sequentially, it fell 58.9% from the prior quarter. Over 3 fiscal years it compounded at -2.0% a year.

Context

  • Inventory amounted to 3.4% of revenue in FY2025, up 3.2 pp from a year earlier.
  • Inventory increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +40.8% toward the trailing-twelve-month pace of +233.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$19.33M-58.9% QoQ
Last fiscal yearJun 2025
-$44.29M-1777.2% YoY
LTMMar 2026
-$98.7M+233.4% YoY
Inventory past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+40.8%——
1 year-1777.2%——
3-year CAGR-2.0%——
5-year CAGR——
10-year CAGR——

Inventory history

USD · from the cash flow

Latest · FY2025
(44.29M) USD
Year-over-year change
-1777.2%

Inventory vs competitors

How PAHC compares with its peers on the latest reported figures

  • Peers report in different currencies, so inventory is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +233.4% is the 2nd highest of 5, against a peer median of +143.5%.
  • Inventory amounts to 6.6% of revenue for PAHC, versus a peer median of 1.8%.
PAHC Competitors
Inventory for PAHC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRKMerck & Co., Inc.LTM Jun 2026$1.18B USD—+94.2%1.8%
ZTSZoetis Inc.LTM Jun 2026$168M USD+80.6%-25.7%1.8%
PAHCPhibro Animal Health CorporationLTM Mar 2026$98.7M USD+233.4%-2.0%6.6%
NEOGNeogen CorporationLTM Aug 2026$36.36M USD+546.9%+56.6%4.1%
ZYBTZhengye Biotechnology Holding LimitedFY2025CN¥6.25M CNY+206.3%—5.4%
ELANElanco Animal Health IncorporatedLTM Sep 2026$0 USD-100.0%-40.4%0.0%
Peer median (excluding PAHC) —+143.5%+15.4%1.8%

Competitors are the stored peer set for PAHC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Net Income54.39M49.18M32.61M2.42M48.26M
Depreciation & Amortization31.89M32.71M34.01M36.18M45.61M
Deferred Income Tax(2.18M)(806K)(2.84M)(7.84M)(4.88M)
Stock-Based Compensation1.13M00475K717K
Change in Working Capital(29.87M)(44.64M)(41.13M)33.11M(21.56M)
Accounts Receivables(18.21M)(23.63M)5.34M(8.68M)(55.21M)
Inventory(12.5M)(47M)(11.22M)2.64M(44.29M)
Accounts Payables3.18M26.36M(22.83M)12M45.56M
Other Working Capital(2.34M)(373K)(12.42M)27.15M32.39M
Other Non-Cash Items(7.04M)(4.79M)(9.34M)23.25M11.98M
Operating Cash Flow48.31M31.65M13.31M87.59M80.12M
Capital Expenditures(29.32M)(37.04M)(51.79M)(41.24M)(38.29M)
Acquisitions (Net)29.32M(13.51M)0(3.28M)(286.53M)
Purchases of Investments(74M)(64.1M)(40M)(65.52M)(14M)
Sales of Investments86M91.45M17M61.52M49M
Other Investing Activities(30.58M)620K776K326K1.13M
Investing Cash Flow(18.58M)(22.58M)(74.02M)(48.19M)(288.69M)
Debt Repayment5.38M40.63M42.69M12.71M235.99M
Common Stock Issued00000
Common Stock Repurchased00000
Dividends Paid(19.43M)(19.44M)(19.44M)(19.44M)(19.45M)
Other Financing Activities(2.94M)(4.84M)3.74M(31K)(9.4M)
Financing Cash Flow(17M)16.34M26.99M(6.77M)207.13M
Effect of Forex Changes1.14M(1.37M)754K(3.3M)(1.14M)
Net Change in Cash13.87M24.04M(32.97M)29.33M(2.57M)
Free Cash Flow18.99M(5.4M)(38.48M)46.36M41.83M

Phibro Animal Health Corporation

NASDAQ:PAHC

Intrinsic Alpha fair value

Locked

Current Price

$35.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.